ProShare Advisors
GNCA

ProShare Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

ProShare Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,317
Closed -$11K – 1820
2018
Q1 		$11K Buy
+1,317
New +$10.9K ﹤0.01% 1713

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's GNCA Position: Q2 2018 in Review

ProShare Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2018, closing a stake of 1,317 shares — an estimated $11K sold.

ProShare Advisors first reported a position in GNCA in Q1 2018 and held it in 1 quarter. The position peaked at $11K in Q1 2018. 54 funds tracked by Wall St. Rank hold GNCA as of Q2 2018.

  • ProShare Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
  • ProShare Advisors sold 1,317 Genocea Biosciences, Inc. shares in Q2 2018, an estimated $11K.
  • ProShare Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2018 and held it in 1 quarter.
  • ProShare Advisors's Genocea Biosciences, Inc. position peaked at $11K in Q1 2018.
  • 54 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2018.

Based on ProShare Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.